Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.
Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK, Shah DP; COVID-19 and Cancer Consortium (CCC19). Fu J, et al. Among authors: bilen ma. JAMA Netw Open. 2022 Mar 1;5(3):e224304. doi: 10.1001/jamanetworkopen.2022.4304. JAMA Netw Open. 2022. PMID: 35344045 Free PMC article.
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG. Boilève A, et al. Among authors: bilen ma. J Immunother Cancer. 2018 Dec 27;6(1):159. doi: 10.1186/s40425-018-0482-z. J Immunother Cancer. 2018. PMID: 30591082 Free PMC article.
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Sonpavde G, et al. Among authors: bilen ma. Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8. Cancer. 2019. PMID: 30620391 Free article.
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. Khaki AR, et al. Among authors: bilen ma. Cancer. 2020 Mar 15;126(6):1208-1216. doi: 10.1002/cncr.32645. Epub 2019 Dec 12. Cancer. 2020. PMID: 31829450 Free PMC article.
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Das S, et al. Among authors: bilen ma. Oncologist. 2020 Aug;25(8):669-679. doi: 10.1634/theoncologist.2019-0637. Epub 2020 Jan 14. Oncologist. 2020. PMID: 31943525 Free PMC article.
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P. Miller NJ, et al. Among authors: bilen ma. J Urol. 2020 Jul;204(1):63-70. doi: 10.1097/JU.0000000000000761. Epub 2020 Jan 23. J Urol. 2020. PMID: 31971495 Free PMC article.
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC. Abou Alaiwi S, et al. Among authors: bilen ma. J Immunother Cancer. 2020 Feb;8(1):e000144. doi: 10.1136/jitc-2019-000144. J Immunother Cancer. 2020. PMID: 32066646 Free PMC article.
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors.
Shabto JM, Martini DJ, Liu Y, Ravindranathan D, Brown J, Hitron EE, Russler GA, Caulfield S, Kissick H, Alemozaffar M, Ogan K, Harris WB, Master VA, Kucuk O, Carthon BC, Bilen MA. Shabto JM, et al. Among authors: bilen ma. Cancer Med. 2020 Apr;9(8):2752-2760. doi: 10.1002/cam4.2932. Epub 2020 Feb 25. Cancer Med. 2020. PMID: 32100417 Free PMC article.
206 results